BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a leading manufacturer of cell counting and characterization technologies, will be led by Varshal Davé, UBC's Managing Partner, who will assume the role of Chief Executive Officer. With over 3,000...
Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the company’s spatial biology and biomarker analytics business and expand strategic partnerships supporting customers’ therapeutic development and clinical trials needs. BroadOak recently provided growth equity funding to Flagship Biosciences.Flagship's full...
BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team in September 2022. EmVenio Research is a Decentralized Clinical Trials (DCT) company originally launched as part of Matrix Medical Network in 2020. In 2022, the company was spun out...
Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a provider of cytogenetic, molecular pathology, and genomic profiling solutions. Bill Snider and Aaron Fisher are joining the Board of Flagship Biosciences. The full press release is below. BROOMFIELD, Colo., Aug. 31,...
BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment in Halo Labs as part of the company’s Series C round of growth financing.Halo Labs uses state-of-the-art optics and image processing to support drug development. The funding will help...
BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of its launch as an independent business. The full press release is below. Microsize Launched as Independent Pharma Services Company Meets the Growing Need for US-Based API Solubility and Bioavailability Enhancement Services QUAKERTOWN, Pa....
BroadOak invested in Kemp Proteins, a leading CDMO specializing in the production of novel proteins. The investment will be used to expand Kemp Proteins' bacteria expression and plasmid production services in Frederick, Maryland. The full press release is below. Kemp Proteins Secures $5M Growth Financing from BroadOak...
BroadOak invested in LabVoice, a company that leverages device, software, and customized workflows to enable the automated lab. Led by entrepreneurs Frederic Bost and Matt Hahn, the pair have deep experience building market-leading scientific software companies. LabVoice’s offering results in optimal lab processes that create...
BroadOak is pleased to announce its investment in Biolog, a leading provider of cell-based microbial identification and phenotypic profiling technologies. Operating Partner Robert Wicke will serve as CEO of Biolog. Bill Snider and Robert Wicke will also serve on the company's Board of Directors. The full...
BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies,...
Stay connected
Partner with BroadOak